m-30

MAO-IN-M30 dihydrochloride is a highly potent non-selective inhibitor of MAO-A and MAO-B (IC50 < 0.1 μM). MAO-IN-M30 dihydrochloride is orally active and can cross the blood-brain barrier. It is an effective iron chelator and free radical scavenger. MAO-IN-M30 dihydrochloride has neuroprotective activity in in vitro and in vivo models of Parkinson's disease (PD). It increases brain dopamine, serotonin and norepinephrine and can serve as a lead drug for the development of multifunctional drugs to treat various neurodegenerative diseases.

M30 peptide is an MHCII-class epitope antigen valuable for research in cancer nanovaccines.

CBM-301940 (compound 5) is a potent and orally active MCD (Malonyl-CoA Decarboxylase) inhibitor with IC50=23 nM that improves cardiac efficiency and function with cardioprotective properties in a rat cardiac ischemia/reperfusion model.

UM-3006 is a potent TLR7/8 agonist that enhances immune responses by activating the TLR signaling pathway. This compound holds significant research and application potential in the fields of vaccine adjuvants and immune diseases.

ETM-305 is a degradation product derived from the anticancer agent ET-743. ET-743, also known as Ecteinascidin 743 or Trabectedin, is a tetrahydroisoquinoline alkaloid that binds to the minor groove of DNA. It disrupts the transcription of stress-induced proteins, induces DNA backbone cleavage, promotes apoptosis in cancer cells, and increases ROS generation in MCF-7 and MDA-MB-453 cells. Trabectedin is studied in the context of soft tissue sarcoma and ovarian cancer.

AFM-30a hydrochloride is a potent and highly selective inhibitor of protein arginine deiminase 2 (PAD2). AFM-30a hydrochloride binds to PAD2 (EC50: 9.5 μM) and inhibits H3 guanylation (EC50: 0.4 μM). AFM-30a hydrochloride can be used to study certain cancers and autoimmune diseases such as rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis.

ZM-306416 (CB 676475) hydrochloride is a potent inhibitor of VEGFR, demonstrating IC50 values of 0.1 µM for KDR and 2 µM for Flt. Additionally, this compound acts as an inhibitor of EGFR with an IC50 value of less than 10 nM.

HM-30181 mesylate monohydrate is an oral P-glycoprotein (P-gp) inhibitor, used to enhance the oral bioavailability of P-gp substrate drugs.

FM-303 is a monoclonal antibody inhibitor that targets interleukin-23 (IL-23). It shows promise for research in immune system and digestive system diseases.

Anti-CLDN6 Antibody (IM-301) is a CHO-expressed human antibody targeting CLDN6. It features an IgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa.

LM-305 is an antibody-drug conjugate (ADC) targeting GPRC5D, composed of a humanised monoclonal antibody against GPRC5D, a degradable protease linker, and the cytotoxic agent MMAE, and can be used for research on multiple myeloma and solid tumours.

Encequidar mesylate (HM30181A mesylate) is a competitive P-glycoprotein inhibitor.

ZM 306416 (CB 676475), a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM).

CM304 free base (FTC-146) is a potent antagonist of the sigma-1 receptor (S1R). It enhances the analgesic effects of cannabinoid receptor agonists and also inhibits seizures in rats.

RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.

Carotegrast methyl (AJM300), an orally-active small molecule, can antagonize the α4 integrin receptor. It is a specific and dual α4β1/α4β7 integrin antagonist.

HM30181AK is an inhibitor of the adenosine triphosphate (ATP) binding cassette (ABC) transporter P-glycoprotein (P-gp) with adjuvant activity.

Rastim 30 dkv is a plant growth regulator based on bensoline.

PSAM (pharmacologically selective actuator module) agonist. Activates PSAML141F-GlyR chimeric ion channels. Inhibits activity of neurons expressing PSAML141F-GlyR in vivo and activates locus coeruleus noradrenergic neurons expressing PSAML141F,Y115F-5-HT3 ion channels. Recommended concentration for use in mice is 5 mg/kg or lower. Plasmid vectors for the transfection of cells with PSAML141F-GlyR and PSAML141F,Y115F-5-HT3 are available from Addgene. Lovett-Barron et al (2012) Regulation of neuronal input transformations by tunable dendritic inhibition. Nat.Neurosci. 15 423 PMID:22246433 |Satoh et al (2016) Context-dependent gait choice elicited by EphA4 mutation in Lbx1 spinal interneurons. Neuron 89 1046 PMID:26924434 |Atasoy et al (2012) Deconstruction of a neural circuit for hunger. Nature 488 172 PMID:22801496 |Hirschberg et al (2017) Functional dichotomy in spinal- vs prefrontal-projecting locus coeruleus modules splits descending noradrenergic analgesia from ascending aversion and anxiety in rats. Elife 6 e29808 PMID:29027903

ALM301 is a highly specific, orally active AKT inhibitor that acts on AKT1 (IC50: 0.13 μM), AKT2 (IC50: 0.09 μM) and AKT3 (IC50: 2.75 μM). ALM301 inhibits AKT phosphorylation in vitro and has a regulatory effect on downstream signalling. ALM301 exhibits inhibitory effects on cancer cell proliferation and tumor growth.

Encequidar, also known as HM-30181, is an oral P-glycoprotein (P-gp) inhibitor developed to enhance the oral bioavailability of P-gp substrate drugs. Encequidar showed the highest potency (IC(50)=0.63nM) among several MDR1 inhibitors, including cycloporin A, XR9576, and GF120918, and effectively blocked transepithelial transport of paclitaxel in MDCK monolayers (IC(50)=35.4nM). Encequidar is currently under clinical trials.

KNI 174 is a new type of anti‐AIDS drug used as an HIV‐1 protease inhibitor

AM-8508 is a potent and selective PI3Kδ inhibitor. AM-8508 showed good cellular potency (in vitro pAKT IC50 = 4.6 nM ). AM-8505 xhibited excellent HWB potency (HWB (pAKT) IC50 = 2.7 nM). AM-8508 inhibit KLH-specific antibodies in animal models, signifying its potential for the treatment of human inflammatory diseases. PI3Kα and PI3Kβ are ubiquitously expressed and play a role in cell growth, division, and survival.

CM304 is a highly selective sigma-1 receptor antagonist.